Fry D W, Besserer J A, Boritzki T J
Cancer Res. 1984 Aug;44(8):3366-70.
Cl-920 is a structurally novel antitumor antibiotic which has activity against a wide spectrum of tumor cells in vitro and is curative in L1210 leukemia in vivo. Several lines of evidence indicate that this drug penetrates L1210 cells via the reduced folate carrier system. Reduced folates (100 microM) including leucovorin and 5-methyltetrahydrofolate completely protected L1210 cells from growth inhibition by Cl-920. Protective effects were not observed, however, with folic acid, a compound which is transported by a process distinct from that for reduced folates. Cl-920 was a potent inhibitor of methotrexate influx exhibiting a mixture of competitive and noncompetitive inhibition and having a Ki (slope) of 30.0 microM and a Ki (intercept) of 58.8 microM. The inhibition appeared to be irreversible since, after cells were preincubated with drug, the inhibitory effects persisted after cells were washed in drug-free media. The irreversibility could be eliminated, however, by dithiothreitol, suggesting that Cl-920 may interact with a thiol which is essential to this transport system. Cells made 71-fold resistant to Cl-920 by continuous exposure to increasing concentrations of this drug were 245-fold cross-resistant to methotrexate but were collaterally sensitive to the lipophilic antifolate trimetrexate and contained normal levels of dihydrofolate reductase. This mutant cell line had a severely impaired reduced folate carrier system exhibiting methotrexate influx rates of less than 1% of control cells. Finally, inhibition of methotrexate influx by a number of Cl-920 analogues showed that the intact lactone ring and the presence of the phosphate ester were required for maximum interaction with the carrier system and that the degree of inhibition correlated with relative antitumor potency. These observations are compatible with the concept that Cl-920 utilizes the folate carrier system and could be of fundamental importance for understanding the cytotoxicity and selectivity of Cl-920.
Cl-920是一种结构新颖的抗肿瘤抗生素,在体外对多种肿瘤细胞具有活性,在体内对L1210白血病具有治疗作用。多项证据表明,该药物通过还原型叶酸载体系统进入L1210细胞。包括亚叶酸和5-甲基四氢叶酸在内的还原型叶酸(100微摩尔)可完全保护L1210细胞免受Cl-920的生长抑制。然而,叶酸(一种通过与还原型叶酸不同的过程转运的化合物)未观察到保护作用。Cl-920是甲氨蝶呤内流的有效抑制剂,表现出竞争性和非竞争性抑制的混合作用,其Ki(斜率)为30.0微摩尔,Ki(截距)为58.8微摩尔。这种抑制作用似乎是不可逆的,因为在细胞与药物预孵育后,在无药物培养基中洗涤细胞后,抑制作用仍然存在。然而,二硫苏糖醇可以消除这种不可逆性,这表明Cl-920可能与该转运系统所必需的一种硫醇相互作用。通过连续暴露于浓度不断增加的该药物而对Cl-920产生71倍抗性的细胞,对甲氨蝶呤有245倍的交叉抗性,但对亲脂性抗叶酸药物三甲曲沙呈侧链敏感,并且二氢叶酸还原酶水平正常。这种突变细胞系的还原型叶酸载体系统严重受损,甲氨蝶呤内流速率不到对照细胞的1%。最后,多种Cl-920类似物对甲氨蝶呤内流的抑制作用表明,完整的内酯环和磷酸酯的存在是与载体系统最大程度相互作用所必需的,并且抑制程度与相对抗肿瘤效力相关。这些观察结果与Cl-920利用叶酸载体系统的概念相符,对于理解Cl-920的细胞毒性和选择性可能具有重要意义。